Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Low incidence of hemorrhagic cystitis following ex vivo T-cell depleted haploidentical hematopoietic cell transplantation in children

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation"

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Chimeric antigen receptor-T-cellebehandling

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-term health outcomes in survivors of childhood AML treated with allogeneic HSCT: a NOPHO-AML Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Hemorrhagic cystitis (HC) is a debilitating complication following allogenic hematopoietic cell transplantation (HCT). HLA disparity and T-cell depletion have been implicated as risk factors for HC. However, reports on the incidence and risk factors for HC in ex vivo T-cell depleted haploidentical HCT (haploHCT) in children are lacking. We studied 96 haploHCT procedures performed in 83 children between 2002 and 2017. Sixty-three patients were diagnosed with a malignant disease and 20 with nonmalignant disease. All but three patients with SCID underwent myelotoxic and/or lymphotoxic conditioning therapy. Grafts were CD3+ (36.5%) or TcRαβ+ (63.5%) depleted to prevent graft versus host disease (GvHD). Fourteen patients (14.6%) were diagnosed with HC; 12 (12.5%) had clinically significant stage II-IV HC. All patients with HC had BK viruria and/or viremia. Increasing age and chemotherapeutic treatment prior to conditioning were identified as risk factors for HC. Immune recovery did not significantly differ between patients with and without HC. Thus, we report a low incidence of HC in pediatric haploHCT using ex vivo T-cell depletion. The combination of a reduced toxicity conditioning regimen, and typically absent pharmaceutical post-HCT GvHD prophylaxis in our patients might have contributed to the decreased the risk of HC, despite HLA disparity.

OriginalsprogEngelsk
TidsskriftBone Marrow Transplantation
Vol/bind55
Udgave nummer1
Sider (fra-til)207-214
Antal sider8
ISSN0268-3369
DOI
StatusUdgivet - 2020

ID: 58992745